TD Cowen Forecasts Strong Price Appreciation for Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences (NASDAQ:EXAS) had its price objective raised by TD Cowen from $82.00 to $86.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

Several other research firms also recently commented on EXAS. BTIG Research upped their target price on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday. Jefferies Financial Group boosted their price target on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Piper Sandler lowered their price objective on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, November 21st. Finally, Evercore ISI decreased their price target on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $75.29.

Exact Sciences Trading Up 9.0 %

Shares of NASDAQ:EXAS opened at $60.10 on Tuesday. The company’s 50-day moving average price is $64.51 and its two-hundred day moving average price is $55.85. Exact Sciences has a one year low of $40.62 and a one year high of $79.62. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The stock has a market capitalization of $11.12 billion, a PE ratio of -51.37 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. On average, equities analysts forecast that Exact Sciences will post -1.13 EPS for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In related news, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the transaction, the executive vice president now directly owns 13,687 shares of the company’s stock, valued at $958,090. The trade was a 6.36 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin T. Conroy bought 19,500 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were purchased at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the transaction, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.36% of the company’s stock.

Institutional Trading of Exact Sciences

Large investors have recently bought and sold shares of the business. Huntington National Bank boosted its position in shares of Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Exact Sciences during the 2nd quarter worth approximately $29,000. RPg Family Wealth Advisory LLC bought a new position in shares of Exact Sciences during the 3rd quarter worth approximately $34,000. Capital Performance Advisors LLP acquired a new stake in shares of Exact Sciences during the 3rd quarter worth approximately $35,000. Finally, Vestor Capital LLC bought a new stake in shares of Exact Sciences in the 3rd quarter valued at $46,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.